MDGL vs. NBIX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MDGL and NBIX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MDGL | NBIX |
|---|---|---|
| Company Name | Madrigal Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 8.73 billion USD | 13.21 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | February 6, 2007 | May 23, 1996 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MDGL and NBIX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MDGL | NBIX |
|---|---|---|
| 5-Day Price Return | 5.46% | 1.46% |
| 13-Week Price Return | 34.72% | 8.48% |
| 26-Week Price Return | 11.36% | 14.00% |
| 52-Week Price Return | 52.56% | -10.13% |
| Month-to-Date Return | 29.47% | 3.90% |
| Year-to-Date Return | 26.93% | -2.40% |
| 10-Day Avg. Volume | 0.45M | 0.84M |
| 3-Month Avg. Volume | 0.37M | 1.17M |
| 3-Month Volatility | 48.92% | 23.38% |
| Beta | -1.10 | 0.21 |
Profitability
Return on Equity (TTM)
MDGL
-38.38%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MDGL has a negative Return on Equity of -38.38%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
NBIX
13.22%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, NBIX’s Return on Equity of 13.22% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
MDGL
-54.68%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MDGL has a negative Net Profit Margin of -54.68%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
NBIX
13.88%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
NBIX’s Net Profit Margin of 13.88% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
MDGL
-60.09%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MDGL has a negative Operating Profit Margin of -60.09%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
NBIX
19.72%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
NBIX’s Operating Profit Margin of 19.72% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | MDGL | NBIX |
|---|---|---|
| Return on Equity (TTM) | -38.38% | 13.22% |
| Return on Assets (TTM) | -27.32% | 9.39% |
| Net Profit Margin (TTM) | -54.68% | 13.88% |
| Operating Profit Margin (TTM) | -60.09% | 19.72% |
| Gross Profit Margin (TTM) | 96.28% | 98.49% |
Financial Strength
Current Ratio (MRQ)
MDGL
5.11
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MDGL’s Current Ratio of 5.11 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
NBIX
3.20
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
NBIX’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
MDGL
0.17
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MDGL’s Debt-to-Equity Ratio of 0.17 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NBIX
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
NBIX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
MDGL
-163.11
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
MDGL has a negative Interest Coverage Ratio of -163.11. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
NBIX
6.75
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
NBIX’s Interest Coverage Ratio of 6.75 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | MDGL | NBIX |
|---|---|---|
| Current Ratio (MRQ) | 5.11 | 3.20 |
| Quick Ratio (MRQ) | 4.48 | 3.10 |
| Debt-to-Equity Ratio (MRQ) | 0.17 | 0.00 |
| Interest Coverage Ratio (TTM) | -163.11 | 6.75 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MDGL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MDGL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
MDGL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MDGL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | MDGL | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
MDGL
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MDGL is currently unavailable.
NBIX
37.70
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
NBIX’s P/E Ratio of 37.70 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
MDGL
16.97
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
MDGL’s P/S Ratio of 16.97 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
NBIX
5.23
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
NBIX’s P/S Ratio of 5.23 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
MDGL
9.65
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MDGL’s P/B Ratio of 9.65 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
NBIX
4.62
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
NBIX’s P/B Ratio of 4.62 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | MDGL | NBIX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 37.70 |
| Price-to-Sales Ratio (TTM) | 16.97 | 5.23 |
| Price-to-Book Ratio (MRQ) | 9.65 | 4.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 253.68 | 24.84 |